SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Orchid Pharma - Quaterly Results

23 May 2024 Evaluate
The total revenue for the quarter ended March 2024 remained nearly unchanged at Rs. 2171.02 millions.Profit after Tax for the quarter ended March 2024 saw a decline of -49.66% from Rs. 659.31 millions to Rs. 331.87  millions.Operating profit for the quarter ended March 2024 rose to 418.10 millions as compared to 414.17 millions of corresponding quarter ended March 2023.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202403 202303 % Var 202403 202303 % Var 202403 202303 % Var
Sales 2171.02 2099.01 3.43 8193.68 6658.98 23.05 8193.68 6658.98 23.05
Other Income 128.85 17.29 645.23 303.89 194.30 56.40 303.89 194.30 56.40
PBIDT 418.10 414.17 0.95 1410.70 1030.49 36.90 1410.70 1030.49 36.90
Interest 34.47 74.84 -53.94 163.28 322.26 -49.33 163.28 322.26 -49.33
PBDT 383.63 731.43 -47.55 1247.42 1100.33 13.37 1247.42 1100.33 13.37
Depreciation 84.02 72.12 16.50 332.19 547.87 -39.37 332.19 547.87 -39.37
PBT 299.61 659.31 -54.56 915.23 552.46 65.66 915.23 552.46 65.66
TAX -32.26 0.00 0.00 -32.26 0.00 0.00 -32.26 0.00 0.00
Deferred Tax -32.26 0.00 0.00 -32.26 0.00 0.00 -32.26 0.00 0.00
PAT 331.87 659.31 -49.66 947.49 552.46 71.50 947.49 552.46 71.50
Equity 507.19 408.16 24.26 507.19 408.16 24.26 507.19 408.16 24.26
PBIDTM(%) 19.26 19.73 -2.40 17.22 15.48 11.25 17.22 15.48 11.25

Orchid Pharma Share Price

567.50 22.55 (4.14%)
15-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1696.65
Dr. Reddys Lab 1218.30
Cipla 1226.65
Zydus Lifesciences 936.00
Lupin 2339.20
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×